EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Research on the treatment of rifampin-susceptible tuberculosis—Time for a new approach

William Burman, Oxana Rucsineanu, C Robert Horsburgh iD, James Johnston iD, Susan E Dorman, Dick Menzies

PLOS Medicine · 25.07.2024 · 21 (7) · e1004438

DOI: 10.1371/journal.pmed.1004438 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Medicine, online erschienen am 25.07.2024. Verfasst von William Burman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Public Health Institute at Denver Health and the Department of Medicine, University of Colorado, Denver, Colorado, United States of America. Hauptthemen laut MEDLINE: Rifampin, Antitubercular Agents, Tuberculosis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the Perspective, William Burman and colleagues advocate improving the safety and acceptability of treatment, rather than treatment-shortening, of rifampin-susceptible tuberculosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifampinAntitubercular AgentsTuberculosisHumansMycobacterium tuberculosis

Substanzen

RifampinAntitubercular Agents

Autor:innen und Institutionen

  • Public Health Institute at Denver Health and the Department of Medicine, University of Colorado, Denver, Colorado, United States of America.
  • Moldova National Association of Tuberculosis Patients "SMIT" (Society of Moldova against Tuberculosis), Balti, Moldova; Global TB Community Advisory Board, New York, New York, United States of America.
  • Departments of Global Health, Epidemiology, Biostatistics and Medicine, Schools of Public Health and Medicine, Boston University, Boston Massachusetts, United States of America.
  • Division of Respiratory Medicine, University of British Columbia, Vancouver, Canada.
  • Division of Infectious Diseases, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, United States of America.
  • McGill International TB Centre, Montreal Chest Institute, Research Institute of the McGill University Health Centre, Montreal, Canada.

ORCID-Profile: C Robert Horsburgh, James Johnston

Zitieren

APA

Burman, W., Rucsineanu, O., Horsburgh, C. R., Johnston, J., Dorman, S. E., & Menzies, D. (2024). Research on the treatment of rifampin-susceptible tuberculosis—Time for a new approach. PLOS Medicine, 21(7), e1004438. https://doi.org/10.1371/journal.pmed.1004438

Vancouver

Burman W, Rucsineanu O, Horsburgh CR, Johnston J, Dorman SE, Menzies D. Research on the treatment of rifampin-susceptible tuberculosis—Time for a new approach. PLOS Medicine. 2024;21(7):e1004438. doi:10.1371/journal.pmed.1004438

BibTeX
@article{Burman2024,
  author = {Burman, William and Rucsineanu, Oxana and Horsburgh, C Robert and Johnston, James and Dorman, Susan E and Menzies, Dick},
  title = {Research on the treatment of rifampin-susceptible tuberculosis—Time for a new approach},
  journal = {PLOS Medicine},
  year = {2024},
  volume = {21},
  number = {7},
  pages = {e1004438},
  doi = {10.1371/journal.pmed.1004438}
}
Kostenlos starten →